Literature DB >> 9544384

Comparison of thallium-201 and gallium-67 scintigraphy in the evaluation of non-Hodgkin's lymphoma.

P J Roach1, R A Cooper, C K Arthur, R B Ravich.   

Abstract

BACKGROUND: Gallium-67 (Ga-67) is widely used in the assessment of patients with lymphoma. Although highly sensitive in Hodgkin's disease and high grade non-Hodgkin's lymphoma (NHL), its sensitivity is reported to be reduced in lower grades of NHL. Several series have suggested that thallium-201 (Tl-201) may be more useful than Ga-67 in the evaluation of low and possibly intermediate grade NHL. AIM: To compare the sensitivity and relative avidities (uptakes) of Tl-201 and Ga-67 in patients with NHL.
METHODS: A total of 36 pairs of studies were performed in 33 patients (14 male: 19 female; age range 16-84 years, mean 55 years). All had whole body Ga-67 (400 MBq) and Tl-201 (100-200 MBq) studies (interval 0-three days) which were read by two experienced nuclear medicine physicians blinded to clinical history and results of other investigations.
RESULTS: Tl-201 had a higher sensitivity and avidity than Ga-67 in patients with low grade NHL. In contrast, Ga-67 was slightly more sensitive and had a higher avidity in patients with both intermediate and high grade NHL.
CONCLUSIONS: We conclude that Tl-201 is more sensitive and avid for low grade NHL than Ga-67 and that consideration should be given to its use in this condition in conjunction with Ga-67 as it may provide complementary information. Routine use in intermediate grade NHL is less convincing as Ga-67 was superior in most cases. Ga-67 is more sensitive than Tl-201 in assessment of high grade NHL.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9544384     DOI: 10.1111/j.1445-5994.1998.tb04456.x

Source DB:  PubMed          Journal:  Aust N Z J Med        ISSN: 0004-8291


  1 in total

1.  Rubidium Uptake in Chest Tumors on PET/CT.

Authors:  Jorge D Oldan; Abiola D Femi-Abodunde; Mitchel A Muhleman; Amir H Khandani
Journal:  World J Nucl Med       Date:  2022-02-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.